Spyre Therapeutics Management
Management criteria checks 0/4
Spyre Therapeutics' CEO is Cameron Turtle, appointed in Oct 2023, has a tenure of 1.17 years. total yearly compensation is $16.17M, comprised of 1.7% salary and 98.3% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth $17.82M. The average tenure of the management team and the board of directors is 1.2 years and 1.5 years respectively.
Key information
Cameron Turtle
Chief executive officer
US$16.2m
Total compensation
| CEO salary percentage | 1.7% |
| CEO tenure | 1.2yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.2yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
Spyre Therapeutics: Different Name, Same Tune
Dec 12Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
Oct 01Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$215m |
| Jun 30 2024 | n/a | n/a | -US$186m |
| Mar 31 2024 | n/a | n/a | -US$364m |
| Dec 31 2023 | US$16m | US$273k | -US$339m |
Compensation vs Market: Cameron's total compensation ($USD16.17M) is above average for companies of similar size in the US market ($USD5.54M).
Compensation vs Earnings: Insufficient data to compare Cameron's compensation with company performance.
CEO
Cameron Turtle (34 yo)
1.2yrs
Tenure
US$16,174,660
Compensation
Dr. Cameron Turtle, D.Phil, Ph D, joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023 and serves as its Chief Executive Officer and Director at Spyre...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.2yrs | US$16.17m | 1.27% $ 17.8m | |
| Chief Financial Officer | 1.3yrs | US$7.55m | 0.026% $ 362.9k | |
| Chief Legal Officer & Corporate Secretary | 1.3yrs | US$6.93m | 0% $ 0 | |
| Senior Vice President of Operations | no data | no data | no data | |
| Chief Technical Officer | 1.1yrs | no data | no data | |
| Vice President of Finance & Investor Relations | no data | no data | no data | |
| Vice President of Quality & Compliance | no data | no data | no data | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Senior Vice President of People | no data | no data | no data | |
| Consultant | 1.6yrs | US$865.79k | no data | |
| Senior Vice President of Clinical Development | 1.1yrs | no data | no data |
1.2yrs
Average Tenure
44yo
Average Age
Experienced Management: SYRE's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$16.17m | 1.27% $ 17.8m | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Independent Chairman of the Board | 1.1yrs | US$433.57k | 0.047% $ 652.7k | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Independent Director | 1.5yrs | US$658.43k | 0.69% $ 9.7m | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 1.1yrs | US$434.38k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$660.78k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$661.28k | 0.69% $ 9.7m |
1.5yrs
Average Tenure
44yo
Average Age
Experienced Board: SYRE's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spyre Therapeutics, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Julian Harrison | BTIG |